Cargando…

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer

Development of metastases to central nervous system (CNS) is an increasing clinical issue following the diagnosis of advanced breast cancer. The propensity to metastasize to CNS varies by breast cancer subtype. Of the four breast cancer subtypes, triple-negative breast cancers (TNBC) have the highes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Jiaojiao, Chernikova, Sophia B., Wang, Yuelong, Rodriguez, Mirna L., Andersen, Stephanie J., Umeh-Garcia, Maxine C., Godfrey, Bryanna O., Ahmadian, Saman S., Fischer, Wolf-Nicolas, Koller, Kerry J., Jandeleit, Bernd, Ringold, Gordon M., Gephart, Melanie Hayden
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2021
Materias:	MCT First Disclosures
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571036/ https://www.ncbi.nlm.nih.gov/pubmed/34635566 http://dx.doi.org/10.1158/1535-7163.MCT-21-0140

Ejemplares similares

LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS
por: Deng, Jiaojiao, et al.
Publicado: (2019)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
por: Murray, Brion W., et al.
Publicado: (2021)

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
por: Roulston, Anne, et al.
Publicado: (2022)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
por: Smith, Bryan D., et al.
Publicado: (2021)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies
por: Zimmermann, Astrid, et al.
Publicado: (2022)

Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
por: Darvishi, Emad, et al.
Publicado: (2022)

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
por: Rigby, Michael, et al.
Publicado: (2022)

Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
por: Li, Xiaofan, et al.
Publicado: (2023)

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic
por: Rossmueller, Gregor, et al.
Publicado: (2023)

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
por: Mazahreh, Rebecca, et al.
Publicado: (2023)

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
por: Kong, Chao, et al.
Publicado: (2023)

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
por: Toader, Dorin, et al.
Publicado: (2023)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Disclosures
Publicado: (2016)

A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma
por: Ozawa, Tomoko, et al.
Publicado: (2021)

Conflict of Interest Disclosures
Publicado: (2017)

Conflict of Interest Disclosures
Publicado: (2018)

Conflict of Interest Disclosures
Publicado: (2019)

Conflict of Interest Disclosures
Publicado: (2021)

Conflict of Interest Disclosures
Publicado: (2022)

Conflict of Interest Disclosures
Publicado: (2023)

Modulation of CFTR gating by permeant ions
por: Yeh, Han-I, et al.
Publicado: (2015)

Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation
por: Medress, Zachary, et al.
Publicado: (2015)

Cell-Permeant and Photocleavable Chemical Inducer of Dimerization**
por: Zimmermann, Mirjam, et al.
Publicado: (2014)

Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer
por: Umeh-Garcia, Maxine, et al.
Publicado: (2022)

Membrane‐Permeant, Bioactivatable Coumarin Derivatives for In‐Cell Labelling
por: Schultz, Madeleine, et al.
Publicado: (2022)

Single Channel Seeks Permeant Ion for Brief but Intimate Relationship
por: Yellen, Gary
Publicado: (1997)

Reflection coefficients of permeant molecules in human red cell suspensions
Publicado: (1975)

Sodium channel selectivity. Dependence on internal permeant ion concentration
Publicado: (1976)

Influence of Permeant Ions on Gating in Cyclic Nucleotide–gated Channels
por: Holmgren, Miguel
Publicado: (2003)

Block of endplate channels by permeant cations in frog skeletal muscle
Publicado: (1981)

Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors
por: Triarico, Silvia, et al.
Publicado: (2019)

N-Cyanorhodamines: cell-permeant, photostable and bathochromically shifted analogues of fluoresceins
por: Heynck, Lukas, et al.
Publicado: (2022)

A Cell-Permeant Nanobody-Based Degrader That Induces Fetal Hemoglobin
por: Shen, Fangfang, et al.
Publicado: (2022)

Welcoming patients into our eye service
por: Pons, Jonathan
Publicado: (2012)

Epidemiological and genetic considerations in retinoblastoma
por: Fabian, Ido Didi, et al.
Publicado: (2018)

TNM8: The updated TNM classification for retinoblastoma
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cgjcqvdqbrvkunr555krlb501u